The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 30, 2015
Filed:
Aug. 05, 2011
Scott Rollins, Oklahoma City, OK (US);
Richard Alvarez, Edmond, OK (US);
Russell Rother, Oklahoma City, OK (US);
Rodger P. Mcever, Oklahoma City, OK (US);
Ziad S. Kawar, Oklahoma City, OK (US);
Scott Rollins, Oklahoma City, OK (US);
Richard Alvarez, Edmond, OK (US);
Russell Rother, Oklahoma City, OK (US);
Rodger P. McEver, Oklahoma City, OK (US);
Ziad S. Kawar, Oklahoma City, OK (US);
Selexys Pharmaceuticals, Oklahoma City, OK (US);
Oklahoma Medical Research Foundation, Oklahoma City, OK (US);
Abstract
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.